# Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects

> **NCT02263976** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 101 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BEA 2180 BR
- **DRUG:** Placebo
- **DEVICE:** Respimat® A 4
- **DRUG:** Methacholine Chloride
- **DRUG:** Spiriva

## Key facts

- **NCT ID:** NCT02263976
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2004-06
- **Final completion:** —
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02263976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02263976, "Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02263976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*